Medical supplies provider Becton Dickinson prelim Q4 revenue up 8.3%, announces CFO transition

Becton Dickinson and

15/10/2025 21:29

Overview

Becton Dickinson's preliminary Q4 revenue grows 8.3% yr/yr but misses analyst expectations

Full-year fiscal 2025 revenue rises 8.2% on a reported basis

Company expects full-year adjusted EPS at or above midpoint of guidance

Outlook

BD expects full-year fiscal 2025 adjusted EPS at or above midpoint of prior guidance

BD aims to drive growth and margin momentum with strategic investments

Result Drivers

SEGMENT GROWTH - Strong performance in BD Interventional, Advanced Patient Monitoring, and Medication Delivery Solutions contributed to revenue growth

CHALLENGES IN PHARMA AND BIOSCIENCES - Greater than anticipated impact in Pharmaceutical Systems vaccines and Biosciences academic and government research affected results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$5.89 bln
$5.91 bln (12 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Becton Dickinson and Co is $205.50, about 8.3% above its October 14 closing price of $188.36

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nPnbYhjSna

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)